Ocata Therapeutics, Inc. (OCAT) - Financial and Strategic SWOT Analysis Review

Date: May 26, 2015
Pages: 49
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OCBFA04A96CEN
Leaflet:

Download PDF Leaflet

Ocata Therapeutics, Inc. (OCAT) - Financial and Strategic SWOT Analysis Review
Ocata Therapeutics, Inc. (OCAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Ocata Therapeutics, Inc. (Ocata) formerly known as Advanced Cell Technology, Inc. is a clinical stage biotechnology company that specializes in regenerative medicine. The company develops and commercializes for various ophthalmological disorders including Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. It key development programs include RPE Cell Therapy; Photoreceptor Progenitor Cell Therapy; Ganglion Progenitor Cell Therapy and Corneal Endothelial Cells. The company also has projects in preclinical development for various indications including autoimmune, inflammatory and wound healing-related disorders. It operates a laboratory and manufacturing facility in Marlborough, in the US. Ocata is headquartered in Marlborough, Massachusetts, the US.

Ocata Therapeutics, Inc. Key Recent Developments

Mar 17, 2015: Ocata Therapeutics Receives Regulatory Guidance from European Medicines Agency
Feb 25, 2015: Ocata Therapeutics Receives Two New Patents for Immune-modulatory Cell Technology
Feb 03, 2015: Ocata Therapeutics Appoints John Heffernan, Vice President of Manufacturing
Dec 18, 2013: Advanced Cell Technology Announces Release of New Edition of Definitive Resource in Tissue Engineering
Dec 12, 2013: Advanced Cell Technology Appoints Eddy Anglade M.D. Executive Vice President of Clinical Development

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Ocata Therapeutics, Inc. - Key Facts
Ocata Therapeutics, Inc. - Key Employees
Ocata Therapeutics, Inc. - Key Employee Biographies
Ocata Therapeutics, Inc. - Major Products and Services
Ocata Therapeutics, Inc. - Pharmaceutical Pipeline Products Data
Ocata Therapeutics, Inc., Pipeline Products by Therapy Area
Ocata Therapeutics, Inc., Pipeline Products by Development Phase
Ocata Therapeutics, Inc. - History
Ocata Therapeutics, Inc. - Company Statement
Ocata Therapeutics, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Ocata Therapeutics, Inc. - Business Description
Ocata Therapeutics, Inc. - Corporate Strategy
Ocata Therapeutics, Inc. - SWOT Analysis
SWOT Analysis - Overview
Ocata Therapeutics, Inc. - Strengths
Strength - Focused Research Expertise
Strength - Patent Portfolio: Intellectual Property
Strength - Strategic Collaborative Agreements
Ocata Therapeutics, Inc. - Weaknesses
Weakness - Lack of Marketed Products
Ocata Therapeutics, Inc. - Opportunities
Opportunity - Orphan Drug Designation
Opportunity - Market Potential: Age-related Macular Degeneration
Opportunity - Growth Potential for Stem Cell Therapy
Ocata Therapeutics, Inc. - Threats
Threat - Dependence on Emerging Technologies
Threat - Uncertain R&D Outcomes
Threat - Increasing Competitive Pressures
Ocata Therapeutics, Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Ocata Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Ocata Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Ocata Therapeutics, Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 17, 2015: Ocata Therapeutics Receives Regulatory Guidance from European Medicines Agency
Feb 25, 2015: Ocata Therapeutics Receives Two New Patents for Immune-modulatory Cell Technology
Feb 03, 2015: Ocata Therapeutics Appoints John Heffernan, Vice President of Manufacturing
Nov 14, 2014: Advanced Cell Technology Changes Name to Ocata Therapeutics
Oct 20, 2014: Advanced Cell Technology Appoints LeRoux Jooste as SVP of Business Development & Chief Commercial Officer
Oct 17, 2014: ACT Reports the Publication of Research on the Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells (iPSC)
Sep 05, 2014: Advanced Cell Technology Announces Issuance of Patent Covering Dendritic Cells Manufacturing from Renewable Stem Cell Sources
Sep 02, 2014: Distinguished Scientists Join Advanced Cell Technology’s New Scientific Advisory Board
Jun 24, 2014: Advanced Cell Technology Appoints Paul K. Wotton, Ph.D, President and Chief Executive Officer
Jun 17, 2014: ACTC Plans To Up-List To Nasdaq By End Of Year

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES
Ocata Therapeutics, Inc., Key Facts
Ocata Therapeutics, Inc., Key Employees
Ocata Therapeutics, Inc., Key Employee Biographies
Ocata Therapeutics, Inc., Major Products and Services
Ocata Therapeutics, Inc., Number of Pipeline Products by Therapy Area
Ocata Therapeutics, Inc., Number of Pipeline Products by Development Stage
Ocata Therapeutics, Inc., Pipeline Products By Therapy Area and Development Phase
Ocata Therapeutics, Inc., History
Ocata Therapeutics, Inc., Other Locations
Ocata Therapeutics, Inc., Subsidiaries
Ocata Therapeutics, Inc., Joint Venture
Ocata Therapeutics, Inc., Key Competitors
Ocata Therapeutics, Inc., Ratios based on current share price
Ocata Therapeutics, Inc., Annual Ratios
Ocata Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Ocata Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Ocata Therapeutics, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES
Ocata Therapeutics, Inc., Pipeline Products by Therapy Area
Ocata Therapeutics, Inc., Pipeline Products by Development Phase
Ocata Therapeutics, Inc., Performance Chart (2010 - 2014)
Ocata Therapeutics, Inc., Ratio Charts
Ocata Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Ocata Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015
Skip to top


Ask Your Question

Ocata Therapeutics, Inc. (OCAT) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: